Global Depression Screening Market Opportunities and Forecast 2020-2027
- DLR2112
- 19 September, 2020
- Pharma & Healthcare
- Pages: 120
- Global
Global Depression Screening Market, By Disease (Anxiety, Depression, Mood Disorders, Bipolar Disorders, Eating Disorders and Psychotic Disorders), By Diagnosis (Lab Tests, Psychological Test, and Depression Screening Tests) opportunities and forecast 2020-2027
Market Overview
Depression affects projected one in every 15 adults and affects almost one in six people experience depression at some time in life. Depression can attack at any age however on average it is observed during late teens to mid-20s. Females are more probable than men to experience the depression related disorders.
According to latest estimations from World Health Organization (WHO), over 300 million people are now having depression with increase of over 18% from 2005 to 2015. Depression is kind of psychological condition that causes persons to experience loss of interest, depressed mood, feelings of low or no self-worth, disturbed appetite or sleep, low energy, and a poor concentration. An individual suffering from depression experiences strong emotions of hopelessness, anxiety, negativity and helplessness.
Growing prevalence of various psychological disorder is one of major driver for market growth. Furthermore, increasing funding for R and D and clinical trials are further supporting the growth of market. Additionally, growing awareness about the disorders and treatments, prompt adoption of the new therapies and treatments, and the technological advancement are some of the key factors propelling the market growth.
Segment Overview
Based on type of disease, the market has been divided into anxiety, depression, mood disorders, bipolar disorder, eating disorders, psychotic disorders, and other psychological behaviours and disorders. Anxiety is largest segment and is anticipated to witness a considerable CAGR in the meantime, depression is fastest growing segment.
Further based on diagnosis, market has been characterized into psychological tests, depression screening tests, laboratory tests, and others. Psychological tests are most common form of diagnosis and evaluation of this segment is anticipated to reach considerably higher revenue by 2026.
Regional Overview
The North America holds is the largest market share of the market. This is largely due to the up-to-date treatment and diagnostic options available. Investigation for the psychological health is well funded and also awareness of psychological health disorders, there is demand for various depression and psychological health screening in the region, particularly in nations such as U.S and Canada.
Europe, with the second largest market share, is anticipated to grow considerably over the forecast period. This is due to the similar growth patterns as North America. Germany, the U.K and France are the top markets in this region, and have a strong existence of the major players which further impact the growth.
Competitor overview
Some of major strategies followed by the players operating in global depression screening market include innovation, and acquisition & mergers, product development. North America witnessed high demand for the screening and diagnostic tests due to broad market size and the greater spending power. Furthermore, China Japan, and India are anticipated among the top fastest-growing markets for the depression screening market in the coming years. Pfizer PLC and Eli Lilly are two of the noticeable market players in global depression screening market.
Key Players
Market Segmentation
By Diseases
Market Overview
Depression affects projected one in every 15 adults and affects almost one in six people experience depression at some time in life. Depression can attack at any age however on average it is observed during late teens to mid-20s. Females are more probable than men to experience the depression related disorders.
According to latest estimations from World Health Organization (WHO), over 300 million people are now having depression with increase of over 18% from 2005 to 2015. Depression is kind of psychological condition that causes persons to experience loss of interest, depressed mood, feelings of low or no self-worth, disturbed appetite or sleep, low energy, and a poor concentration. An individual suffering from depression experiences strong emotions of hopelessness, anxiety, negativity and helplessness.
Growing prevalence of various psychological disorder is one of major driver for market growth. Furthermore, increasing funding for R and D and clinical trials are further supporting the growth of market. Additionally, growing awareness about the disorders and treatments, prompt adoption of the new therapies and treatments, and the technological advancement are some of the key factors propelling the market growth.
Segment Overview
Based on type of disease, the market has been divided into anxiety, depression, mood disorders, bipolar disorder, eating disorders, psychotic disorders, and other psychological behaviours and disorders. Anxiety is largest segment and is anticipated to witness a considerable CAGR in the meantime, depression is fastest growing segment.
Further based on diagnosis, market has been characterized into psychological tests, depression screening tests, laboratory tests, and others. Psychological tests are most common form of diagnosis and evaluation of this segment is anticipated to reach considerably higher revenue by 2026.
Regional Overview
The North America holds is the largest market share of the market. This is largely due to the up-to-date treatment and diagnostic options available. Investigation for the psychological health is well funded and also awareness of psychological health disorders, there is demand for various depression and psychological health screening in the region, particularly in nations such as U.S and Canada.
Europe, with the second largest market share, is anticipated to grow considerably over the forecast period. This is due to the similar growth patterns as North America. Germany, the U.K and France are the top markets in this region, and have a strong existence of the major players which further impact the growth.
Competitor overview
Some of major strategies followed by the players operating in global depression screening market include innovation, and acquisition & mergers, product development. North America witnessed high demand for the screening and diagnostic tests due to broad market size and the greater spending power. Furthermore, China Japan, and India are anticipated among the top fastest-growing markets for the depression screening market in the coming years. Pfizer PLC and Eli Lilly are two of the noticeable market players in global depression screening market.
Key Players
- AstraZeneca
- Bristol-Myers Squibb Company
- Allergan
- Eli Lilly
- Novartis AG
- Alkermes
- Pfizer
Market Segmentation
By Diseases
- Anxiety
- Eating Disorders
- Mood Disorders
- Bipolar Disorders
- Depression
- Psychotic Disorders
- Psychological Test
- Depression Screening Test
- Lab Tests
- North America
- US
- Canada
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- UAE
- Rest of LAMEA
1 Report Prologue 12
2 Market Introduction 16
- 2.1 Scope of Study 16
- 2.2 Research Objective 16
- 2.3 Assumptions & Limitations 16
- 2.3.1 Assumptions 16
- 2.3.2 Limitations 16
3 Research Methodology 17
- 3.1 Primary Research Methodology 18
- 3.2 Secondary Research Methodology 19
- 3.3 Market Share Analysis 20
- 3.4 Trade Analysis 20
- 3.5 Market Pricing Approach 20
4 Market Dynamics 21
- 4.1 Introduction 21
- 4.2 Drivers 22
- 4.2.1 Emergence of digital health technologies in mental health (Impact weightage-45%) 22
- 4.2.2 Growing prevalence of mental disorders around the globe (Impact weightage-30%) 23
- 4.2.3 New focus areas in the care continuum are prevention and recovery (Impact weightage-25%) 24
- 4.3 Restraints 25
- 4.3.1 Low public awareness of mental disorders and treatments in emerging nations (Impact weightage-55%) 25
- 4.3.2 Cultural Stigma preventing the market growth (Impact weightage-45%) 26
5 Market Factor Analysis 27
- 5.1 Porter’s Five Forces Model 27
- 5.1.1 Bargaining Power of Suppliers 28
- 5.1.2 Bargaining Power of Buyers 28
- 5.1.3 Threat of New Entrants 28
- 5.1.4 Threat of Substitutes 28
- 5.1.5 Intensity of Rivalry 28
- 5.2 Value Chain Analysis 29
6 Global Depression Screening Market, By Disease Type 30
- 6.1 Introduction 30
- 6.2 Anxiety 32
- 6.3 Mood Disorders 32
- 6.4 Depression 33
- 6.5 Bipolar Disorders 33
- 6.6 Psychotic Disorders 34
- 6.7 Eating Disorders 34
7 Global Depression Screening Market, By Diagnosis 35
- 7.1 Introduction 35
- 7.2 Psychological Test 36
- 7.3 Lab Tests 37
- 7.4 Depression Screening Tests 37
8 Global Depression Screening Market, By Treatment 38
- 8.1 Introduction 38
- 8.2 Medication 40
- 8.3 Brain-Stimulation Treatments 40
- 8.4 Substance Abuse Treatment 41
9 Global Depression Screening Market, By End User 42
- 9.1 Introduction 42
- 9.2 Hospitals & Clinics 43
- 9.3 Medical Research Centers 43
- 9.4 Academic Institutes 44
10 Global Depression Screening Market, By Region 45
- 10.1 Introduction 45
- 10.2 Americas 46
- 10.2.1 U.S. 49
- 10.2.2 Canada 51
- 10.2.3 South America 53
- 10.3 Europe 55
- 10.3.1 Germany 58
- 10.3.2 France 60
- 10.3.3 UK 62
- 10.3.4 Italy 64
- 10.3.5 Spain 66
- 10.3.6 Rest of Western Europe 68
- 10.3.7 Eastern Europe 70
- 10.4 Asia Pacific 72
- 10.4.1 Japan 75
- 10.4.2 China 77
- 10.4.3 India 79
- 10.4.4 Australia 81
- 10.4.5 Republic of Korea 83
- 10.4.6 Rest of Asia Pacific 85
- 10.5 Middle East & Africa 87
- 10.5.1 Middle East 90
- 10.5.2 Africa 92
11 Company Share Analysis 94
12 Company Profiles: Top 7 Players 95
- 12.1 Allergan 95
- 12.1.1 Company Overview 95
- 12.1.2 Financials 95
- 12.1.3 Products 95
- 12.1.4 Strategy 95
- 12.1.5 Key Developments 95
- 12.2 Eli Lilly 96
- 12.2.1 Company Overview 96
- 12.2.2 Financials 96
- 12.2.3 Products 96
- 12.2.4 Strategy 96
- 12.2.5 Key Developments 96
- 12.3 Novartis AG. 97
- 12.3.1 Company Overview 97
- 12.3.2 Financials 97
- 12.3.3 Products 97
- 12.3.4 Strategy 97
- 12.3.5 Key Developments 97
- 12.4 Alkermes 98
- 12.4.1 Company Overview 98
- 12.4.2 Financials 98
- 12.4.3 Products 98
- 12.4.4 Strategy 98
- 12.4.5 Key Developments 98
- 12.5 Bristol-Myers Squibb Company 99
- 12.5.1 Company Overview 99
- 12.5.2 Financials 99
- 12.5.3 Products 99
- 12.5.4 Strategy 99
- 12.5.5 Key Developments 99
- 12.6 Pfizer 100
- 12.6.1 Company Overview 100
- 12.6.2 Financials 100
- 12.6.3 Products 100
- 12.6.4 Strategy 100
- 12.6.5 Key Developments 100
- 12.7 AstraZeneca 101
- 12.7.1 Company Overview 101
- 12.7.2 Financials 101
- 12.7.3 Products 101
- 12.7.4 Srategy 101
- 12.7.5 Key Developments 101
Report You Might be Interested
Choose License Type
- USD
- GBP
- EURO
- INR
